(Q36206061)

12 August 2017

3 references

19 March 2019

24 March 2019

23 November 2020

Post-marketing withdrawal of anti-obesity medicinal products because of adverse drug reactions: a systematic review (English)

1 reference

12 August 2017

2 references

19 March 2019

24 March 2019

adverse drug reaction

1 reference

23 November 2020

1 reference

3

Jeffrey K Aronson

1 reference

12 August 2017

Igho J Onakpoya

1

1 reference

12 August 2017

Carl J Heneghan

series ordinal

2

1 reference

12 August 2017

language of work or name

English

0 references

publication date

29 November 2016

4 references

12 August 2017

19 March 2019

24 March 2019

23 November 2020

4 references

12 August 2017

19 March 2019

24 March 2019

23 November 2020

14

1 reference

12 August 2017

1

1 reference

12 August 2017

191

1 reference

Creative Commons Attribution 4.0 International

12 August 2017

3 references

19 March 2019

24 March 2019

on focus list of Wikimedia project

23 November 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

exact match

https://scigraph.springernature.com/pub.10.1186/s12916-016-0735-y

0 references

cites work

Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

FDA-Approved Anti-Obesity Drugs in the United States

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Herbal weight loss pill overdose: sibutramine hidden in pepper pill

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Management of obesity: improvement of health-care training and systems for prevention and care

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Delays in the post-marketing withdrawal of drugs to which deaths have been attributed: a systematic investigation and analysis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Savings in Medical Expenditures Associated with Reductions in Body Mass Index Among US Adults with Obesity, by Diabetes Status

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Impact of long-term lifestyle programmes on weight loss and cardiovascular risk factors in overweight/obese participants: a systematic review and network meta-analysis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Medical treatment of obesity: the past, the present and the future

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Safety of antiobesity drugs

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Tolerability and safety of the new anti-obesity medications

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Antiobesity pharmacotherapy: new drugs and emerging targets

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

A practical guide to the therapy of narcolepsy and hypersomnia syndromes

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Anti-obesity drugs: past, present and future

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Amfetamine and methylphenidate medications for attention-deficit/hyperactivity disorder: complementary treatment options

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Anti-Obesity Drugs: A Review about Their Effects and Safety

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Drug treatment of obesity in cardiovascular disease

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

2,4-dinitrophenol (DNP): a weight loss agent with significant acute toxicity and risk of death

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Multicenter, placebo-controlled trial of lorcaserin for weight management

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Final rule declaring dietary supplements containing ephedrine alkaloids adulterated because they present an unreasonable risk. Final rule.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

5-HT2A antagonists in psychiatric disorders.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Obesity drug sibutramine (Meridia): hypertension and cardiac arrhythmias.

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Aminorex to fen/phen: an epidemic foretold

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Valvular heart disease associated with fenfluramine-phentermine

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Abuse of Anorexics with Special Reference to Newer Substances

1 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

The new weight-loss drugs, lorcaserin and phentermine-topiramate: slim pickings?

29 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Lorcaserin for weight loss: insights into US Food and Drug Administration approval

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

The return of rainbow diet pills.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Effect of rimonabant on weight and cardiometabolic risk factors

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Treatment and prevention of obesity--are there critical periods for intervention?

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Postmarketing surveillance--lack of vigilance, lack of trust.

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Estimate of deaths due to valvular insufficiency attributable to the use of benfluorex in France

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5126837

Naltrexone + bupropion (Mysimba). Too risky for only modest weight loss

21 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27894343

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Anti-obesity therapies

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27894343

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Approval of antiobesity drug is "major regression for patients' safety," says health watchdog

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27894343

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1186/S12916-016-0735-Y

1 reference

Dimensions Publication ID

12 August 2017

0 references

1 reference

12 August 2017

1 reference